This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Sarcosine
- DrugBank Accession Number
- DB12519
- Background
Sarcosine has been investigated for the treatment of Schizophrenia.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Sarcosine (DB12519)
- Weight
- Average: 89.0932
Monoisotopic: 89.047678473 - Chemical Formula
- C3H7NO2
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as alpha amino acids. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon).
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Amino acids, peptides, and analogues
- Direct Parent
- Alpha amino acids
- Alternative Parents
- Amino acids / Monocarboxylic acids and derivatives / Dialkylamines / Carboxylic acids / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Aliphatic acyclic compound / Alpha-amino acid / Amine / Amino acid / Carbonyl group / Carboxylic acid / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Organic nitrogen compound / Organic oxide
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- N-alkylglycine, N-methyl-amino acid, N-methylglycines (CHEBI:15611)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Z711V88R5F
- CAS number
- 107-97-1
- InChI Key
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N
- InChI
- InChI=1S/C3H7NO2/c1-4-2-3(5)6/h4H,2H2,1H3,(H,5,6)
- IUPAC Name
- 2-(methylamino)acetic acid
- SMILES
- CNCC(O)=O
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0000271
- KEGG Compound
- C00213
- PubChem Compound
- 1088
- PubChem Substance
- 347828749
- ChemSpider
- 1057
- BindingDB
- 50017225
- 1362906
- ChEBI
- 57433
- ChEMBL
- CHEMBL304383
- ZINC
- ZINC000004658561
- PDBe Ligand
- SAR
- Wikipedia
- Sarcosine
- PDB Entries
- 173d / 1a7y / 1a7z / 1bck / 1c5f / 1csa / 1cwa / 1cwb / 1cwc / 1cwf … show 109 more
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Major Depressive Disorder (MDD) 1 2 Completed Treatment Depression / Major Depressive Disorder (MDD) 1 2 Completed Treatment Obsessive Compulsive Disorder (OCD) 1 2 Completed Treatment Psychosis / Schizophrenia 2 2 Completed Treatment Schizophrenia 1 2 Withdrawn Treatment Psychosis / Schizophrenia 1 Not Available Completed Not Available Prostate Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 308.0 mg/mL ALOGPS logP -3.1 ALOGPS logP -3.2 Chemaxon logS 0.54 ALOGPS pKa (Strongest Acidic) 2.06 Chemaxon pKa (Strongest Basic) 10.35 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 49.33 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 20.78 m3·mol-1 Chemaxon Polarizability 8.66 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Drug created at October 20, 2016 22:41 / Updated at June 12, 2020 16:53